Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Deals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Fineline Cube Mar 20, 2025

On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...

Company Deals

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery

Fineline Cube Mar 20, 2025

On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment

Fineline Cube Mar 20, 2025

On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...

Policy / Regulatory

CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 20, 2025

China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...

Company

HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth

Fineline Cube Mar 20, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933

Fineline Cube Mar 20, 2025

French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...

Policy / Regulatory

NMPA Seeks Public Input on Drug Trial Data Protection Measures

Fineline Cube Mar 20, 2025

On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...

Company Medical Device

Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx

Fineline Cube Mar 19, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...

Company Deals Hospital

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Fineline Cube Mar 19, 2025

Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...

Company

Pfizer Restructures China Operations to Boost Growth and Innovation

Fineline Cube Mar 19, 2025

US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...

Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Fineline Cube Mar 19, 2025

The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...

Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

Fineline Cube Mar 19, 2025

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...

Company Deals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Fineline Cube Mar 19, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...

Company Drug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Fineline Cube Mar 19, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...

Company Deals

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries

Fineline Cube Mar 19, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...

Company Drug

AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment

Fineline Cube Mar 19, 2025

China-based AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Orphan Drug Designation (ODD) from the US...

Company Drug

Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease

Fineline Cube Mar 19, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...

Company

Medbanks Reports 2024 Financial Results Amid Business Reorganization

Fineline Cube Mar 19, 2025

Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....

Company Drug

AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer

Fineline Cube Mar 19, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...

Company Drug

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial

Fineline Cube Mar 19, 2025

Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...

Posts pagination

1 … 158 159 160 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.